2,858 Shares in Boston Scientific Corporation $BSX Acquired by DSM Capital Partners LLC

DSM Capital Partners LLC purchased a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,858 shares of the medical equipment provider’s stock, valued at approximately $307,000.

Other large investors have also made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Boston Scientific by 15.4% during the 2nd quarter. GAMMA Investing LLC now owns 29,486 shares of the medical equipment provider’s stock worth $3,167,000 after acquiring an additional 3,932 shares in the last quarter. MRA Advisory Group bought a new position in Boston Scientific in the 2nd quarter valued at approximately $273,000. Bank of New Hampshire lifted its stake in Boston Scientific by 552.0% in the 2nd quarter. Bank of New Hampshire now owns 19,724 shares of the medical equipment provider’s stock valued at $2,119,000 after purchasing an additional 16,699 shares during the last quarter. NS Partners Ltd lifted its stake in Boston Scientific by 1.6% in the 1st quarter. NS Partners Ltd now owns 368,189 shares of the medical equipment provider’s stock valued at $37,143,000 after purchasing an additional 5,704 shares during the last quarter. Finally, Neville Rodie & Shaw Inc. lifted its stake in Boston Scientific by 95.9% in the 2nd quarter. Neville Rodie & Shaw Inc. now owns 45,460 shares of the medical equipment provider’s stock valued at $4,883,000 after purchasing an additional 22,255 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently commented on BSX. Leerink Partners increased their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Robert W. Baird increased their price objective on shares of Boston Scientific from $123.00 to $128.00 and gave the company an “outperform” rating in a research note on Wednesday, October 1st. Canaccord Genuity Group increased their price objective on shares of Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. UBS Group increased their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a “buy” rating in a research note on Thursday, July 24th. Finally, Truist Financial raised their price target on shares of Boston Scientific from $125.00 to $129.00 and gave the company a “buy” rating in a research note on Wednesday, October 1st. Two analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $120.71.

Insider Activity at Boston Scientific

In other Boston Scientific news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction on Wednesday, October 1st. The shares were sold at an average price of $98.47, for a total value of $4,923,500.00. Following the completion of the sale, the executive vice president directly owned 178,342 shares of the company’s stock, valued at approximately $17,561,336.74. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total transaction of $1,811,459.19. Following the transaction, the executive vice president owned 23,600 shares of the company’s stock, valued at $2,469,268. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. 0.50% of the stock is currently owned by company insiders.

Boston Scientific Trading Down 1.9%

BSX opened at $95.41 on Friday. Boston Scientific Corporation has a 1-year low of $80.64 and a 1-year high of $109.50. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The company has a market cap of $141.38 billion, a P/E ratio of 56.79, a price-to-earnings-growth ratio of 2.34 and a beta of 0.61. The company has a fifty day moving average price of $101.98 and a two-hundred day moving average price of $101.87.

Boston Scientific (NYSE:BSX) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The firm had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period in the previous year, the firm posted $0.62 earnings per share. The business’s revenue was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.